Literature DB >> 28176722

Clinical and Lipid Profile Studies in Xanthelasma Palpebrarum.

B S N Reddy, Gurmohan Singh, S S Pandey, D Tiwari.   

Abstract

The clinical cand lipid abnormalities in 45 cases of xanthelasma are reported. Their findings suggest that xanthelasma is seen in some patients as an isolated clinical symptom with normal serum lipid level% representing a local derangement of cellular lipid metabolism. Nevertheless it is noted in many patients with moderate elevation of different serum lipid fractions without any other clinical manifestations, occurring probably as a resultof benign derangement of systemic lipid metabolism. Less frequently, it is observed with significant elevation of serum lipid levels in association with certain grave abnormalities like hypertension, ischaemic heart disease,' familial hypercholesterolemia, familial xanthomatosis, diabetes etc. Thus it is inferred that the symptom xanthelasma signifies disturbed lipid metabolism of several and the, patient needs thorough investigation.

Entities:  

Year:  1983        PMID: 28176722

Source DB:  PubMed          Journal:  Indian J Dermatol Venereol Leprol        ISSN: 0378-6323            Impact factor:   2.545


  3 in total

1.  Serum lipid profile and clinical characteristics of patients with xanthelasma palpebrarum.

Authors:  Hossein Kavoussi; Ali Ebrahimi; Mansour Rezaei; Mazaher Ramezani; Behnaz Najafi; Reza Kavoussi
Journal:  An Bras Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.896

2.  Xanthelasma Is Associated with an Increased Amount of Epicardial Adipose Tissue.

Authors:  Ali Rıza Akyüz; Mustafa Tarık Ağaç; Turhan Turan; Sinan Şahin; Selim Kul; Levent Korkmaz; Musluhittin Emre Erkuş; Hakan Erkan; Şükrü Çelik
Journal:  Med Princ Pract       Date:  2015-10-21       Impact factor: 1.927

3.  Xanthelasma Palpebrarum with Arcus Cornea: A Clinical and Biochemical Study.

Authors:  Pragya Ashok Nair; Chaitali R Patel; Jaishree D Ganjiwale; Nilofar Gulamsha Diwan; Nidhi Bhimjibhai Jivani
Journal:  Indian J Dermatol       Date:  2016 May-Jun       Impact factor: 1.494

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.